Literature DB >> 7037385

Chemotherapy-induced immunosuppression.

L Rasmussen, A Arvin.   

Abstract

Chemotherapeutic agents are used widely in clinical medicine for the treatment of conditions where diminution of the host immune response is a goal. The clinical use of immunosuppression is indicated for immunologically mediated disease, lymphoproliferative diseases, and prevention of graft rejection. Five categories of agents are useful for these purposes; they are ionizing irradiation, corticosteroids, biological alkylating agents, antilymphocyte sera and antimetabolites. While the specific molecular action of many of these drugs is known, how they affect cellular events in immune responses is less clear. One of the unfortunate sequelae of chemotherapy induced immunosuppression is an increased susceptibility of the host to opportunistic pathogens or malignancies. Specific methods are described for monitoring the various parameters of both humoral and cellular immunity. Studies of immunologic function in lymphoma patients and cardiac transplant patients treated with immunosuppressive drugs have shown specific defects in cell mediated immunity to herpes viruses which may relate to their increased susceptibility to infection by these agents.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7037385      PMCID: PMC1568884          DOI: 10.1289/ehp.824321

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  7 in total

1.  NIH conference. Herpes zoster-varicella infections in immunosuppressed patients.

Authors:  R Dolin; R C Reichman; M H Mazur; R J Whitley
Journal:  Ann Intern Med       Date:  1978-09       Impact factor: 25.391

2.  Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma.

Authors:  A M Arvin; R B Pollard; L E Rasmussen; T C Merigan
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

3.  Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients.

Authors:  R B Pollard; K H Rand; A M Arvin; T C Merigan
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

4.  Role of T lymphocytes in cellular immune responses during herpes simplex virus infection in humans.

Authors:  L Rasmussen; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

5.  Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma.

Authors:  A M Arvin; R B Pollard; L E Rasmussen; T C Merigan
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

6.  Prolonged herpes-zoster infection associated with immunosuppressive therapy.

Authors:  J G Gallagher; T C Merigan
Journal:  Ann Intern Med       Date:  1979-12       Impact factor: 25.391

7.  Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus.

Authors:  S Haahr; L Rasmussen; T C Merigan
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

  7 in total
  27 in total

Review 1.  Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.

Authors:  Marco Sisignano; Ralf Baron; Klaus Scholich; Gerd Geisslinger
Journal:  Nat Rev Neurol       Date:  2014-11-04       Impact factor: 42.937

2.  Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.

Authors:  Nate N Waldron; Seunguk Oh; Daniel A Vallera
Journal:  Oral Oncol       Date:  2012-07-20       Impact factor: 5.337

3.  Sickness behavior induced by cisplatin chemotherapy and radiotherapy in a murine head and neck cancer model is associated with altered mitochondrial gene expression.

Authors:  Elisabeth G Vichaya; Jessica M Molkentine; Daniel W Vermeer; Adam K Walker; Rebekah Feng; Gerard Holder; Katherine Luu; Ryan M Mason; Leo Saligan; Cobi J Heijnen; Annemieke Kavelaars; Kathy A Mason; John H Lee; Robert Dantzer
Journal:  Behav Brain Res       Date:  2015-10-22       Impact factor: 3.332

4.  Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity.

Authors:  Stefano Di Biase; Changhan Lee; Sebastian Brandhorst; Brianna Manes; Roberta Buono; Chia-Wei Cheng; Mafalda Cacciottolo; Alejandro Martin-Montalvo; Rafael de Cabo; Min Wei; Todd E Morgan; Valter D Longo
Journal:  Cancer Cell       Date:  2016-07-11       Impact factor: 31.743

5.  Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.

Authors:  David M Peereboom; Tyler J Alban; Matthew M Grabowski; Alvaro G Alvarado; Balint Otvos; Defne Bayik; Gustavo Roversi; Mary McGraw; Pengjing Huang; Alireza M Mohammadi; Harley I Kornblum; Tomas Radivoyevitch; Manmeet S Ahluwalia; Michael A Vogelbaum; Justin D Lathia
Journal:  JCI Insight       Date:  2019-11-14

6.  Colonic diverticulitis in chemotherapy patients: should operative indications change? A retrospective cohort study.

Authors:  Tushar Samdani; Fredric M Pieracci; Soumitra R Eachempati; Jaime Benarroch-Gampel; Alex Weiss; M Cathy Pietanza; Philip S Barie; Garrett M Nash
Journal:  Int J Surg       Date:  2014-11-07       Impact factor: 6.071

Review 7.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

8.  PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

Authors:  Min Thura; Abdul Qader Omer Al-Aidaroos; Wei Peng Yong; Koji Kono; Abhishek Gupta; You Bin Lin; Kousaku Mimura; Jean Paul Thiery; Boon Cher Goh; Patrick Tan; Ross Soo; Cheng William Hong; Lingzhi Wang; Suling Joyce Lin; Elya Chen; Sun Young Rha; Hyun Cheol Chung; Jie Li; Sayantani Nandi; Hiu Fung Yuen; Shu-Dong Zhang; Yeoh Khay Guan; Jimmy So; Qi Zeng
Journal:  JCI Insight       Date:  2016-06-16

9.  Testicular cancer and HPV semen infection.

Authors:  Andrea Garolla; Damiano Pizzol; Alessandro Bertoldo; Marco Ghezzi; Umberto Carraro; Alberto Ferlin; Carlo Foresta
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-21       Impact factor: 5.555

10.  Selenium nanoparticle-enriched Lactobacillus brevis causes more efficient immune responses in vivo and reduces the liver metastasis in metastatic form of mouse breast cancer.

Authors:  Mohammad Hossein Yazdi; Mehdi Mahdavi; Neda Setayesh; Mohammad Esfandyar; Ahmad Reza Shahverdi
Journal:  Daru       Date:  2013-04-30       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.